Last reviewed · How we verify
IC
Interferon-alpha (IC) works by stimulating the body's immune system to fight viral infections and cancer.
At a glance
| Generic name | IC |
|---|---|
| Also known as | Platinol-AQ (cisplatin), CPT-11 (irinotecan) |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Interferon-alpha (IC) is a type of cytokine that plays a crucial role in the body's natural defense against viral infections and cancer. It works by binding to specific receptors on the surface of cells, triggering a cascade of signaling events that ultimately lead to the activation of immune cells and the production of other cytokines that help to eliminate infected cells and tumor cells.
Approved indications
Common side effects
Key clinical trials
- Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (PHASE3)
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis (PHASE1, PHASE2)
- Effects of Including Interferential Current in a Therapeutic Exercise Program in Individuals With Knee Osteoarthritis (NA)
- Screening for Heart Failure in General Medicine Consultations
- Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial (NA)
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |